A laboratory approach for characterizing chronic fatigue : what does metabolomics tell us?

Show simple item record

dc.contributor.author Erasmus, Elardus
dc.contributor.author Mason, Shayne
dc.contributor.author Van Reenen, Mari
dc.contributor.author Steffens, Francois E.
dc.contributor.author Vorster, B. Chris
dc.contributor.author Reinecke, Carolus J.
dc.date.accessioned 2020-06-08T14:40:02Z
dc.date.issued 2019-11
dc.description.abstract INTRODUCTION : Manifestations of fatigue range from chronic fatigue up to a severe syndrome and myalgic encephalomyelitis. Fatigue grossly affects the functional status and quality of life of affected individuals, prompting the World Health Organization to recognize it as a chronic non-communicable condition. OBJECTIVES : Here, we explore the potential of urinary metabolite information to complement clinical criteria of fatigue, providing an avenue towards an objective measure of fatigue in patients presenting with the full spectrum of fatigue levels. METHODS : The experimental group consisted of 578 chronic fatigue female patients. The measurement design was composed of (1) existing clinical fatigue scales, (2) a hepatic detoxification challenge test, and (3) untargeted proton nuclear magnetic resonance (1H-NMR) procedure to generate metabolomics data. Data analysed via an in-house Matlab script that combines functions from a Statistics and a PLS Toolbox. RESULTS : Multivariate analysis of the original 459 profiled 1H-NMR bins for the low (control) and high (patient) fatigue groups indicated complete separation following the detoxification experimental challenge. Important bins identified from the 1H-NMR spectra provided quantitative metabolite information on the detoxification challenge for the fatigue groups. CONCLUSIONS : Untargeted 1H-NMR metabolomics proved its applicability as a global profiling tool to reveal the impact of toxicological interventions in chronic fatigue patients. No clear potential biomarker emerged from this study, but the quantitative profile of the phase II biotransformation products provide a practical visible effect directing to up-regulation of crucial phase II enzyme systems in the high fatigue group in response to a high xenobiotic-load. en_ZA
dc.description.department Consumer Science en_ZA
dc.description.embargo 2020-11-22
dc.description.librarian hj2020 en_ZA
dc.description.sponsorship The Technological Innovation Agency (TIA) of the Department of Science and Technology of South Africa. en_ZA
dc.description.uri http://link.springer.com/journal/11306 en_ZA
dc.identifier.citation Erasmus, E., Mason, S., van Reenen, M. et al. A laboratory approach for characterizing chronic fatigue: what does metabolomics tell us?. Metabolomics 15, 158 (2019). https://doi.org/10.1007/s11306-019-1620-4. en_ZA
dc.identifier.issn 1573-3882 (print)
dc.identifier.issn 1573-3890 (online)
dc.identifier.other 10.1007/s11306-019-1620-4
dc.identifier.uri http://hdl.handle.net/2263/74904
dc.language.iso en en_ZA
dc.publisher Springer en_ZA
dc.rights © Springer Science+Business Media, LLC, part of Springer Nature 2019. The original publication is available at : http://link.springer.comjournal/11306. en_ZA
dc.subject Phase II biotransformation en_ZA
dc.subject 1H-NMR metabolomics en_ZA
dc.subject Chronic fatigue en_ZA
dc.subject Detoxification challenge test en_ZA
dc.subject Piper fatigue scale en_ZA
dc.title A laboratory approach for characterizing chronic fatigue : what does metabolomics tell us? en_ZA
dc.type Postprint Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record